Last reviewed · How we verify
AD-227A
AD-227A is a small molecule drug that targets the serotonin receptor.
AD-227A is a small molecule drug that targets the serotonin receptor. Used for Major depressive disorder, Generalized anxiety disorder.
At a glance
| Generic name | AD-227A |
|---|---|
| Sponsor | Addpharma Inc. |
| Drug class | Serotonin receptor agonist |
| Target | 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
It works by activating the serotonin receptor, which can help to reduce symptoms of depression and anxiety. However, the exact mechanism of action is not fully understood and more research is needed to confirm its effects.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B (PHASE1)
- A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AD-227A CI brief — competitive landscape report
- AD-227A updates RSS · CI watch RSS
- Addpharma Inc. portfolio CI